
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **CLEC4C**: Known as a marker for plasmacytoid dendritic cells (pDCs), involved in immune response.<br>- **LILRA4**: Another marker for pDCs, involved in immune regulation.<br>- **GZMB**: Granzyme B, involved in cytotoxic activity, often found in cytotoxic T cells and NK cells.<br>- **JCHAIN**: Joining chain of multimeric IgA and IgM, associated with B cells and plasma cells.<br>- **IRF8**: Interferon regulatory factor 8, involved in the development of immune cells, particularly dendritic cells.<br>- **SPIB**: Transcription factor involved in B cell development and function.<br>- **IRF7**: Interferon regulatory factor 7, involved in antiviral responses, often expressed in pDCs.<br>- **TCF4**: Transcription factor involved in the development of various immune cells, including pDCs.<br>- **HLA-DRA**: Major histocompatibility complex, class II, DR alpha, involved in antigen presentation, expressed in antigen-presenting cells.<br><br>### Step 2: List the Key Cell Type Markers<br>- **CLEC4C, LILRA4, IRF7, TCF4**: Strongly indicative of plasmacytoid dendritic cells (pDCs).<br>- **JCHAIN, IGKC, IGHM**: Associated with B cells and plasma cells.<br>- **CD4**: Typically expressed in helper T cells, but also in some dendritic cells.<br>- **CXCR3, CXCR4**: Chemokine receptors, often found in T cells and some dendritic cells.<br>- **HLA-DRA, CD74**: Markers for antigen-presenting cells, including dendritic cells.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as CellMarker, PanglaoDB, and literature on scRNA-seq, the combination of markers like CLEC4C, LILRA4, IRF7, and TCF4 is highly specific to plasmacytoid dendritic cells (pDCs). These databases confirm the association of these markers with pDCs, which are known for their role in producing type I interferons and participating in antiviral responses.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of key markers such as CLEC4C, LILRA4, IRF7, and TCF4, the most probable general cell type is **plasmacytoid dendritic cells (pDCs)**.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Plasmacytoid Dendritic Cells (pDCs)**: The presence of CLEC4C, LILRA4, IRF7, and TCF4 strongly supports this subtype.<br>2. **Activated pDCs**: Given the expression of GZMB and IRF8, which can be upregulated in activated pDCs.<br>3. **Immature pDCs**: If markers like CD4 and CXCR4 are more prominent, it could indicate a less mature state of pDCs.<br><br>The most likely subtype based on the markers is **plasmacytoid dendritic cells (pDCs)**, with a potential activation state suggested by the presence of GZMB.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset indicates that the cell cluster is most likely composed of plasmacytoid dendritic cells (pDCs). This conclusion is supported by the expression of key markers such as CLEC4C, LILRA4, IRF7, and TCF4, which are characteristic of pDCs. The presence of additional markers like GZMB suggests a possible activated state of these cells. The identification of pDCs is consistent with their known role in immune surveillance and response within the tumor microenvironment.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation of the cell cluster as plasmacytoid dendritic cells (pDCs) is consistent with the provided marker list and the analysis steps outlined. Here's the breakdown:<br><br>1. **Marker Consistency**: <br>   - The key markers used to identify pDCs, such as CLEC4C, LILRA4, IRF7, and TCF4, are present in the provided marker list.<br>   - Additional markers like GZMB and IRF8, which suggest an activated state of pDCs, are also present in the list.<br>   - The presence of markers like JCHAIN, IGKC, and IGHM, which are associated with B cells and plasma cells, does not conflict with the primary identification of pDCs, as these markers are not the primary focus of the annotation.<br><br>2. **Mixed Cell Type Consideration**:<br>   - While there are markers associated with other cell types (e.g., B cells, plasma cells, T cells), the strong presence and high ranking of pDC-specific markers (CLEC4C, LILRA4, IRF7, TCF4) support the primary annotation of pDCs.<br>   - The potential presence of activated or immature pDCs is acknowledged and supported by the expression of GZMB and other markers like CD4 and CXCR4.<br><br>Overall, the annotation is well-supported by the marker list and the analysis provided, with a clear focus on plasmacytoid dendritic cells (pDCs) as the primary cell type.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">plasmacytoid dendritic cells (pDCs)</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>activated pDCs</li><li>immature pDCs</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">85</div>
                        <div class="scoring-content">
                            The annotation results provided for the single-cell dataset from human breast cancer tissue are generally well-executed, with a strong focus on identifying plasmacytoid dendritic cells (pDCs) as the primary cell type. The analysis effectively uses key markers such as CLEC4C, LILRA4, IRF7, and TCF4, which are well-established indicators of pDCs. This demonstrates a solid understanding of the marker profiles associated with this cell type.<br><br>Strengths:<br>1. **Correctness of Annotations**: The identification of pDCs is scientifically accurate, given the presence of specific markers like CLEC4C and LILRA4. The analysis also considers the potential activation state of these cells, supported by markers such as GZMB and IRF8.<br>2. **Balanced Consideration of Markers**: The annotation does not overly focus on a single marker but rather considers a combination of markers to support the identification of pDCs. This approach is crucial for accurate cell type annotation.<br>3. **Comprehensive View**: The analysis acknowledges the presence of markers associated with other cell types (e.g., B cells, plasma cells) but justifies the primary focus on pDCs due to the dominance and ranking of pDC-specific markers.<br><br>Weaknesses:<br>1. **Potential Oversight of Mixed Cell Types**: While the annotation acknowledges the presence of markers associated with other cell types, it does not explore the possibility of mixed cell populations in detail. This could be a limitation if the dataset contains significant proportions of other immune cells.<br>2. **Marker Ranking Consideration**: The analysis could benefit from a more explicit discussion of the importance of marker ranking. While the presence of key pDC markers is noted, the relative importance of their ranking in the list could be more clearly articulated.<br><br>Overall, the annotation is robust and captures the general picture of the cell populations present, with a clear focus on pDCs. However, a more detailed exploration of potential mixed cell types and a stronger emphasis on marker ranking would enhance the analysis.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    